HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >

Pretreatment of Hepatocyte Growth Factor Gene Transfer Mediated by Octaarginine Peptide-Modified Nanoparticles Ameliorates LPS/D-Galactosamine-Induced Hepatitis

Files in This Item:
NAT22-5_360-363.pdf128.27 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/50423

Title: Pretreatment of Hepatocyte Growth Factor Gene Transfer Mediated by Octaarginine Peptide-Modified Nanoparticles Ameliorates LPS/D-Galactosamine-Induced Hepatitis
Authors: Hayashi, Yasuhiro Browse this author →KAKEN DB
Mizuno, Ryoichi Browse this author
Ikramy, Khalil A. Browse this author
Akita, Hidetaka Browse this author →KAKEN DB
Harashima, Hideyoshi Browse this author →KAKEN DB
Issue Date: 2-Oct-2012
Publisher: Mary Ann Liebert
Journal Title: Nucleic Acid Therapeutics
Volume: 22
Issue: 5
Start Page: 360
End Page: 363
Publisher DOI: 10.1089/nat.2012.0352
Abstract: We previously reported that an octaarginine- and pH-sensitive fusogenic peptide-modified multifunctional envelope-type nano device (R8-GALA-MEND) produces a high level of gene expression in the liver. In this study, we report on an examination of whether this gene delivery system exerts potent hepatoprotective effects against lipopolysaccharide/D-galactosamine (LPS/D-GalN)-induced acute liver injury. In vivo-jetPEI^[TM]-Gal, a commercially available in vivo transfection reagent, was used as a reference. The systemic administration of the R8-GALA-MEND or in vivo-jetPEI^[TM]-Gal showed that the latter was more toxic than the R8-GALA-MEND, indicating that R8-GALA-MEND is a safer system than in vivo-jetPEI^[TM]-Gal. Pretreatment with R8-GALA-MEND or in vivo-jetPEI^[TM]-Gal loaded with hepatocyte growth factor (HGF) pDNA inhibited serum GPT and GOT levels from becoming elevated. However, the survival rate of the mice was significantly enhanced in the case of R8-GALA-MEND, but not for the in vivo-jetPEI^[TM]-Gal treatment. These results demonstrate that R8-GALA-MEND has the potential for use in the pretreatment of an acute liver injury.
Rights: This is a copy of an article published in the Nucleic Acid Therapeutics © 2012 copyright Mary Ann Liebert, Inc.; Nucleic Acid Therapeutics is available online at: http://online.liebertpub.com.
Type: article
URI: http://hdl.handle.net/2115/50423
Appears in Collections:薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 林 泰弘

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University